May 20, 2021
Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per day).
AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable to current lateral flow rapid tests.
Moving to complete product registration in Indonesia and progressing to securing a CE mark in Europe with a view to approvals and sales in Q3 2021.
ZURICH, SWITZERLAND - EQS Newswire - 20 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) completed production of the first 1,000 AptameX test kits and has commenced shipment to Indonesia. The Company also announces favourable preliminary Covid-19 diagnostic testing results at a high CT score; even at low viral loads, AptameX proves to be highly sensitive.
Achiko AG / Key word(s): Preliminary Results
Achiko AG: Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% sensitivity at low viral loads
20-May-2021
The issuer is solely responsible for the content of this announcement. Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% sensitivity at low viral loads - Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per day). - AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable to current lateral flow rapid tests.